The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The global expansion of modern AML therapy through the International Consortium on Acute Leukemia
Eduardo Rego, MD, University of São Paulo, São Paulo, Brazil, provides insight into the international expansion of modern acute myeloid leukemia (AML) therapy through the work of the International Consortium on Acute Leukemia (ICAL). This global initiative, supported by the American Society of Hematology (ASH), aims to bring together clinical investigators from Europe, North America, and South America to improve the outcomes of patients with AML and other acute leukemias through clinical and laboratory collaboration. The ICAL has already improved the infrastructure for conducting molecular diagnosis and helped to decrease mortality rates during induction therapy. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
